Skip to main content

Table 1 Characteristics of the three study groups

From: Pentraxin-3 in non-alcoholic fatty liver disease and its affection by concomitant chronic hepatitis C infection

ParameterGroup Ι
NAFLD patients (n = 25)
Group ΙΙ
NAFLD patients with HCV (n = 25)
Group ΙΙΙ
Healthy control (N = 20)
Mean ± SD
Age (in years)42.7 ± 11.243.3 ± 9.642.4 ± 6.9
Body weight (Kg)94.8 ± 16.879.6 ± 10.169.7 ± 4.7
Height (cm)167.7 ± 8.9171.2 ± 9.8171.3 ± 3.2
Body mass index (Kg/m2)33.0 ± 5.126.7 ± 2.423.7 ± 1.6
Waist circumference (cm)110.8 ± 15.098.8 ± 9.583.9 ± 8.0
PCR for HCV (IU/mL)-765,324.9 ± 1,510,564.0-
ALT (U/L)45.1 ± 20.475.4 ± 27.113.9 ± 2.1
AST (U/L)40.6 ± 16.952.6 ± 20.410.7 ± 1.8
Albumin (g/dL)4.1 ± 0.24.1 ± 0.55.5 ± 0.4
Total bilirubin (mg/dL)0.8 ± 0.20.7 ± 0.20.3 ± 0.1
Direct bilirubin (mg/dL)0.3 ± 0.10.2 ± 0.10.1 ± 0.04
Hemoglobin (g/dL)13.5 ± 1.213.1 ± 1.214.4 ± 0.6
 WBC (˟103/cmm)8.1 ± 1.27.2 ± 2.28.5 ± 0.8
 PLT (˟103/cmm)256.5 ± 63.2226.2 ± 48.6297.0 ± 20.5
Serum creatinine (mg/dL)0.8 ± 0.20.8 ± 0.20.8 ± 0.1
Urea (mg/dL)19.2 ± 3.117.2 ± 2.118.5 ± 2.0
Fasting blood sugar (mg/dL)98.2 ± 48.478.1 ± 11.570.2 ± 4.6
Post prandial blood sugar (mg/dL)125.6 ± 44.8103.3 ± 19.492.0 ± 4.2
Triglyceride (mg/dL)203.2 ± 75.0161.2 ± 16.2108.4 ± 10.6
 HDL (mg/dL)35.4 ± 3.833.8 ± 2.441.5 ± 6.1
 LDL (mg/dL)164.7 ± 24.3146.4 ± 11.188.6 ± 7.9
Total Cholesterol (mg/dL)222.2 ± 30.5195.6 ± 12.3157.3 ± 5.7
Plasma PTX3 (ng/mL)5.5 ± 4.95.8 ± 4.50.9 ± 0.5
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, HCV hepatitis C virus, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD nonalcoholic fatty liver disease, PTX3 pentraxin-3